The Cigna Group
Explore The Cigna Group
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
The Cigna Group is a managed healthcare and pharmacy benefit management company with $274.9B in FY2025 revenue and about 67,700 employees worldwide. The company operates at the intersection of insurance risk, employer benefits, Evernorth pharmacy services, and clinical cost management under Chairman and CEO David M. Cordani.
The business model of The Cigna Group is a sophisticated, multi-layered financial and operational network designed to manage the profound actuarial and clinical risks of human health while extracting value from the inefficiencies of the United States healthcare and pharmaceutical systems. Fundamentally, the company operates as a fully integrated managed care organization, functioning as the critical financial intermediary between employers, government entities, and individual consumers on one side, and the vast network of healthcare providers and pharmaceutical manufacturers on the other. The primary engine of the company's revenue and operational complexity is divided into two distinct but deeply interconnected segments: Cigna Healthcare and Evernorth Health Services. The Cigna Healthcare segment operates as a traditional health insurer, collecting premiums from its millions of medical members. These premiums are pooled into a massive reservoir of capital, from which the company pays for the medical claims incurred by its members. The fundamental economic metric that dictates the profitability of this segment is the Medical Loss Ratio (MLR), which represents the percentage of premium dollars spent on actual medical claims and healthcare quality improvement activities. By regulation, Cigna must spend a minimum of 80 to 85 percent of its premium revenue on medical care, meaning the gross margin on its insurance products is inherently capped and exceptionally thin. Therefore, the company's financial success in this segment relies entirely on its ability to manage the denominator—the total cost of medical claims—through aggressive care management, network negotiation, and the promotion of value-based care arrangements. By shifting provider reimbursement from traditional fee-for-service models to capitated or bundled payment arrangements, Cigna aligns the financial incentives of the providers with its own, encouraging preventative care and reducing expensive hospital readmissions. However, the traditional pure-payer model, while generating enormous top-line revenue, is increasingly constrained by regulatory caps on MLR and the immense bargaining power of consolidating hospital systems. Recognizing this structural limitation, Cigna has executed a profound strategic evolution through the creation and massive scaling of the Evernorth Health Services segment. Evernorth represents the company's definitive shift into the direct management of healthcare services, encompassing pharmacy benefit management (PBM) through its wholly-owned subsidiary Express Scripts, specialty pharmacy distribution, and care delivery solutions. The economics of the PBM model are fundamentally different from traditional health insurance. PBMs act as intermediaries between health plans, pharmaceutical manufacturers, and retail pharmacies. Here's why: they generate revenue through a complex web of mechanisms, including negotiating rebates and discounts from drug manufacturers in exchange for favorable formulary placement, managing pharmacy networks, and using spread pricing—where the PBM charges the health plan more for a drug than it reimburses the pharmacy. Cigna has increasingly moved toward pass-through pricing models, where rebates are passed directly to the client, generating revenue through transparent administrative fees rather than opaque spread margins. This shift has been driven by client demand for transparency and regulatory pressure, but it has also allowed Cigna to capture massive volume in the highly lucrative specialty pharmacy market. Specialty drugs, which include high-cost biologics, oncology treatments, and the rapidly expanding class of GLP-1 weight-loss and diabetes medications, represent the fastest-growing segment of pharmaceutical spending. By internalizing the specialty pharmacy supply chain through Evernorth, Cigna captures the distribution margins and clinical management fees associated with these ultra-expensive medications, creating a massive, high-volume revenue stream. While the top-line revenue of the PBM segment is enormous, the gross margins are relatively thin because a significant portion of the revenue represents the pass-through cost of the drugs themselves. Therefore, the true financial value of Evernorth lies in its ability to generate substantial operating income through administrative fees, clinical program management, and its critical role in suppressing the overall medical cost trends for the Cigna Healthcare insurance segment. The integration of Cigna Healthcare and Evernorth creates a powerful closed-loop network. By owning both the health plan and the PBM, Cigna can directly align the clinical and financial incentives across the entire care continuum. For example, if a member is prescribed a high-cost specialty drug, Evernorth can manage the prior authorization, ensure the member receives the medication through a specialized clinical protocol, and monitor their adherence. If the medication successfully manages the patient's chronic condition, it prevents expensive hospitalizations and emergency room visits, thereby reducing the medical claims paid out by the Cigna Healthcare insurance segment. This internal alignment allows Cigna to deploy advanced predictive analytics to identify high-risk patients, intervene earlier in the care continuum, and improved the total cost of care. Geographically and demographically, the company's business model is highly diversified, balancing the high-margin, employer-sponsored commercial book with the high-volume, lower-margin government programs and the massive, fee-based PBM operations. This diversified membership base insulates the company from the cyclical fluctuations of the employer-sponsored market and the political volatility of government healthcare budgets. Ultimately, The Cigna Group business model is a masterclass in scale economics, risk management, and vertical integration. By using its immense size to negotiate favorable reimbursement rates with providers and pharmaceutical manufacturers, deploying advanced analytics to predict and prevent high-cost medical events, and fully integrating its insurance and pharmacy operations, the company has constructed a resilient financial engine capable of generating hundreds of billions in revenue and substantial free cash flow, even amidst the relentless cost pressures and regulatory complexities of the American healthcare landscape.
Chairman and Chief Executive Officer
Cordani is Chairman and Chief Executive Officer, leading Cigna's integrated health services strategy across Cigna Healthcare and Evernorth.
President and Chief Operating Officer
Evanko became President and Chief Operating Officer in March 2025 after serving in senior finance and Cigna Healthcare leadership roles.
Executive Vice President and Chief Financial Officer
Dennison is Executive Vice President and Chief Financial Officer of The Cigna Group.
Despite its significant market position and massive scale, The Cigna Group faces a complex matrix of existential, operational, and regulatory challenges that threaten to impede its growth trajectory and compress its historically solid profit margins. The most immediate and pervasive challenge is the intense and escalating legislative and regulatory scrutiny directed at the pharmacy benefit management industry. Over the past several years, PBMs have become the primary political target for lawmakers, patient advocacy groups, and independent pharmacies, who argue that the opaque rebate mechanisms, spread pricing practices, and formulary manipulation employed by the 'Big Three' PBMs artificially inflate drug costs and harm consumers. This scrutiny has resulted in a wave of state-level legislation aimed at mandating rebate transparency, banning spread pricing in Medicaid programs, and restricting the ability of PBMs to own specialty pharmacies. At the federal level, the Federal Trade Commission has launched comprehensive investigations into PBM practices, and Congress has held numerous hearings exploring antitrust concerns and the impact of PBMs on drug affordability. Navigating this hostile regulatory environment requires Cigna to continuously adapt its PBM pricing models, often at the expense of its most profitable legacy revenue streams, while defending its business practices against potentially devastating legislative mandates. Beyond the PBM regulatory crosshairs, Cigna is grappling with the relentless upward pressure on medical cost trends and the rebound in healthcare use following the pandemic-induced suppression. The company has experienced a significant increase in the use of high-acuity medical services, including elective surgeries, inpatient admissions, and the escalating cost of high-end pharmaceuticals, particularly the explosive demand for GLP-1 weight-loss and diabetes medications. While GLP-1 drugs drive massive revenue volume through the Evernorth specialty pharmacy channel, their ultra-high list prices and broad potential patient population pose a severe threat to the medical loss ratio of the Cigna Healthcare insurance segment. Managing the clinical and financial impact of these specialty drugs represents a monumental challenge, as the company struggles to balance the long-term health benefits of these medications against their immediate, devastating impact on short-term medical and pharmacy cost trends. The company faces intense operational challenges in integrating and optimizing its massive, complex IT and clinical infrastructure. The 2018 acquisition of Express Scripts was one of the largest mergers in corporate history, and the ongoing process of aligning the data systems, clinical protocols, and corporate cultures of a massive health insurer and a massive PBM requires continuous, heavy capital investment. Any friction in this integration can lead to operational inefficiencies, client dissatisfaction, and the loss of market share to more flexible competitors. Finally, the regulatory environment for Medicare Advantage is becoming increasingly restrictive, with the Centers for Medicare & Medicaid Services implementing stricter risk-adjustment coding validation rules and revising the Star Ratings methodology. A downgrade in Star Ratings can result in hundreds of millions in lost bonus revenue and severely damage a plan's competitive positioning during the annual enrollment period. Navigating these multifaceted challenges requires The Cigna Group to operate with flawless execution, balancing aggressive cost management with relentless innovation, all while defending its core franchises against an increasingly hostile political and regulatory environment.
David Cordani is CEO of The Cigna Group.
Cordani emphasizes Evernorth growth and affordable care coordination.
Earlier leaders managed Cigna through prior managed-care expansion eras.
CEO eras map onto PBM integration and medical-cost cycles.